Crossmark Global Holdings Inc. Acquires 252 Shares of argenx SE (NASDAQ:ARGX)

Crossmark Global Holdings Inc. boosted its holdings in argenx SE (NASDAQ:ARGX) by 2.7% in the 4th quarter, HoldingsChannel reports. The firm owned 9,714 shares of the company’s stock after purchasing an additional 252 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in argenx were worth $5,974,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ARGX. Profund Advisors LLC boosted its position in shares of argenx by 3.0% during the second quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after acquiring an additional 28 shares during the last quarter. Raymond James Trust N.A. boosted its holdings in shares of argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock valued at $268,000 after purchasing an additional 28 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of argenx by 8.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock valued at $286,000 after purchasing an additional 43 shares during the last quarter. Aaron Wealth Advisors LLC increased its holdings in shares of argenx by 10.1% in the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock worth $301,000 after purchasing an additional 45 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Up 1.1 %

Shares of argenx stock opened at $647.39 on Wednesday. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21. The company has a market capitalization of $39.08 billion, a PE ratio of -735.67 and a beta of 0.59. The stock’s fifty day moving average is $622.29 and its two-hundred day moving average is $560.29.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same period in the prior year, the business posted ($1.25) earnings per share. As a group, research analysts anticipate that argenx SE will post 2.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $717.00 price target (up previously from $670.00) on shares of argenx in a report on Tuesday, January 14th. Guggenheim raised their target price on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a report on Friday, November 1st. Citigroup increased their price objective on shares of argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and boosted their target price for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. Finally, Evercore ISI increased their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.